31/120
1.3 / 5 stars
All 120 Win/Lose results shown below
ASMB Roast Me summary
ASSEMBLY BIOSCIENCES, INC. (ASMB). Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
- 2026-Q2: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Win; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Win; EPS growth Lose.
Trailing 1 year (4 quarters): 6 wins, 6 lossesLast fetched: 25 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
LoseASMB / S&P -0.97% / 15.20% |
WinASMB / S&P 125.12% / 15.00% |
LoseASMB / S&P ASMB unavailable / 50.40% |
| 2026-Q11/3 |
LoseASMB / S&P -18.41% / -4.33% |
WinASMB / S&P 121.11% / 11.30% |
LoseASMB / S&P ASMB unavailable / 27.70% |
| 2025-Q42/3 |
WinASMB / S&P 32.85% / 2.65% |
WinASMB / S&P 153.52% / 9.00% |
LoseASMB / S&P ASMB unavailable / 13.40% |
| 2025-Q32/3 |
WinASMB / S&P 41.28% / 8.12% |
WinASMB / S&P 31.30% / 4.61% |
LoseASMB / S&P ASMB unavailable / 13.45% |
| 2025-Q22/3 |
WinASMB / S&P 89.54% / 10.94% |
WinASMB / S&P 54.77% / 4.83% |
LoseASMB / S&P ASMB unavailable / 10.63% |
| 2025-Q11/3 |
LoseASMB / S&P -39.42% / -4.27% |
WinASMB / S&P 148.33% / 4.98% |
LoseASMB / S&P ASMB unavailable / 10.57% |
| 2024-Q42/3 |
WinASMB / S&P 4.23% / 2.41% |
WinASMB / S&P 298.16% / 5.25% |
LoseASMB / S&P ASMB unavailable / 6.15% |
| 2024-Q31/3 |
WinASMB / S&P 10.35% / 5.89% |
LoseASMB / S&P ASMB unavailable / 5.89% |
LoseASMB / S&P ASMB unavailable / 6.11% |
| 2024-Q20/3 |
LoseASMB / S&P 3.16% / 4.28% |
LoseASMB / S&P ASMB unavailable / 5.38% |
LoseASMB / S&P ASMB unavailable / 5.12% |
| 2024-Q11/3 |
WinASMB / S&P 35.16% / 10.56% |
LoseASMB / S&P ASMB unavailable / 5.71% |
LoseASMB / S&P ASMB unavailable / 5.59% |
| 2023-Q40/3 |
LoseASMB / S&P -7.87% / 11.69% |
LoseASMB / S&P ASMB unavailable / 6.81% |
LoseASMB / S&P ASMB unavailable / 7.78% |
| 2023-Q30/3 |
LoseASMB / S&P -22.61% / -3.27% |
LoseASMB / S&P ASMB unavailable / 7.52% |
LoseASMB / S&P ASMB unavailable / -5.03% |
| 2023-Q21/3 |
WinASMB / S&P 36.90% / 8.74% |
LoseASMB / S&P ASMB unavailable / 9.50% |
LoseASMB / S&P ASMB unavailable / -8.57% |
| 2023-Q10/3 |
LoseASMB / S&P -35.38% / 7.50% |
LoseASMB / S&P ASMB unavailable / 10.77% |
LoseASMB / S&P ASMB unavailable / -15.69% |
| 2022-Q40/3 |
LoseASMB / S&P -20.73% / 7.56% |
LoseASMB / S&P -100.00% / 11.88% |
LoseASMB / S&P ASMB unavailable / -17.99% |
| 2022-Q30/3 |
LoseASMB / S&P -21.90% / -4.88% |
LoseASMB / S&P ASMB unavailable / 13.47% |
LoseASMB / S&P ASMB unavailable / -1.41% |
| 2022-Q21/3 |
WinASMB / S&P 1.94% / -16.10% |
LoseASMB / S&P ASMB unavailable / 13.71% |
LoseASMB / S&P ASMB unavailable / 11.04% |
| 2022-Q10/3 |
LoseASMB / S&P -11.59% / -4.60% |
LoseASMB / S&P ASMB unavailable / 15.97% |
LoseASMB / S&P ASMB unavailable / 42.23% |
| 2021-Q40/3 |
LoseASMB / S&P -33.05% / 11.03% |
LoseASMB / S&P -92.09% / 15.00% |
LoseASMB / S&P ASMB unavailable / 96.40% |
| 2021-Q30/3 |
LoseASMB / S&P -10.31% / 0.58% |
LoseASMB / S&P ASMB unavailable / 10.77% |
LoseASMB / S&P ASMB unavailable / 69.42% |
| 2021-Q20/3 |
LoseASMB / S&P -15.65% / 8.55% |
LoseASMB / S&P ASMB unavailable / 6.58% |
LoseASMB / S&P ASMB unavailable / 51.81% |
| 2021-Q10/3 |
LoseASMB / S&P -23.97% / 6.17% |
LoseASMB / S&P ASMB unavailable / -1.06% |
LoseASMB / S&P ASMB unavailable / 7.39% |
| 2020-Q41/3 |
LoseASMB / S&P -63.20% / 12.15% |
WinASMB / S&P 395.55% / -3.72% |
LoseASMB / S&P ASMB unavailable / -33.42% |
| 2020-Q31/3 |
LoseASMB / S&P -29.50% / 8.93% |
WinASMB / S&P 454.78% / -2.04% |
LoseASMB / S&P ASMB unavailable / -27.10% |
| 2020-Q22/3 |
WinASMB / S&P 57.25% / 20.54% |
WinASMB / S&P 250.02% / -0.46% |
LoseASMB / S&P ASMB unavailable / -27.11% |
| 2020-Q11/3 |
LoseASMB / S&P -27.52% / -19.60% |
WinASMB / S&P 6.84% / 3.47% |
LoseASMB / S&P ASMB unavailable / -14.75% |
| 2019-Q42/3 |
WinASMB / S&P 108.14% / 9.07% |
WinASMB / S&P 7.83% / 5.36% |
LoseASMB / S&P ASMB unavailable / 2.99% |
| 2019-Q30/3 |
LoseASMB / S&P -27.13% / 1.70% |
LoseASMB / S&P 3.80% / 5.02% |
LoseASMB / S&P ASMB unavailable / 0.21% |
| 2019-Q21/3 |
LoseASMB / S&P -31.49% / 4.30% |
WinASMB / S&P 17.46% / 6.64% |
LoseASMB / S&P ASMB unavailable / 8.65% |
| 2019-Q11/3 |
LoseASMB / S&P -12.95% / 13.65% |
WinASMB / S&P 27.10% / 8.12% |
LoseASMB / S&P ASMB unavailable / 14.29% |
| 2018-Q41/3 |
LoseASMB / S&P -39.10% / -13.52% |
WinASMB / S&P 64.14% / 9.05% |
LoseASMB / S&P ASMB unavailable / 18.23% |
| 2018-Q30/3 |
LoseASMB / S&P -5.28% / 7.71% |
LoseASMB / S&P ASMB unavailable / 10.21% |
LoseASMB / S&P ASMB unavailable / 19.06% |
| 2018-Q20/3 |
LoseASMB / S&P -20.21% / 3.43% |
LoseASMB / S&P ASMB unavailable / 9.03% |
LoseASMB / S&P ASMB unavailable / 14.46% |
| 2018-Q11/3 |
WinASMB / S&P 8.60% / -0.76% |
LoseASMB / S&P ASMB unavailable / 7.68% |
LoseASMB / S&P ASMB unavailable / 12.46% |
| 2017-Q41/3 |
WinASMB / S&P 29.58% / 6.64% |
LoseASMB / S&P ASMB unavailable / 7.03% |
LoseASMB / S&P ASMB unavailable / 13.82% |
| 2017-Q31/3 |
WinASMB / S&P 69.10% / 4.48% |
LoseASMB / S&P ASMB unavailable / 5.68% |
LoseASMB / S&P ASMB unavailable / 17.57% |
| 2017-Q20/3 |
LoseASMB / S&P -18.99% / 3.09% |
LoseASMB / S&P ASMB unavailable / 4.83% |
LoseASMB / S&P ASMB unavailable / 17.74% |
| 2017-Q11/3 |
WinASMB / S&P 109.79% / 6.07% |
LoseASMB / S&P ASMB unavailable / 3.67% |
LoseASMB / S&P ASMB unavailable / 13.32% |
| 2016-Q41/3 |
WinASMB / S&P 68.52% / 3.82% |
LoseASMB / S&P ASMB unavailable / 2.09% |
LoseASMB / S&P ASMB unavailable / 7.05% |
| 2016-Q31/3 |
WinASMB / S&P 29.91% / 3.85% |
LoseASMB / S&P ASMB unavailable / 0.20% |
LoseASMB / S&P ASMB unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-28
| Metric | ASMB total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 37.74% | 20.78% |
| Annualized return | 37.74% | 20.78% |
5Y · 2021-09-01 to 2026-08-28
| Metric | ASMB total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -27.30% | 83.14% |
| Annualized return | -6.18% | 12.86% |
10Y · 2016-09-01 to 2026-08-28
| Metric | ASMB total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -54.64% | 319.30% |
| Annualized return | -7.60% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-25.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |